July 2021

At Cipla, we constantly work towards ensuring access to high quality and affordable medicines to support patients in need. Which is why, we have been trusted by health care professionals and patients across geographies for the last 8 decades.

Campus Drive 2021
Organised by
N N Sattha College of Pharmacy Ahmednagar

MSN Group is one of the fastest growing manufacturers of Active Pharmaceutical Ingredients (APIs) and Finished dosages in India. Established in the year 2003, MSN Group comprises of 330 API manufacturing plants (including one for Oncology), three finished dosage facility ( including one for Oncology)and a dedicated R&D Center . Our plants are ISO 9001-2000 certified, WHO: GMP, EU:GMP and USFDA approved.

API DIVISION : R&D DEPARTMENT

Vital Therapeutics and Formulations Private Limited is an endeavour to offer trustworthy partnership comprising superior quality products and services par excellence in Contract Manufacturing, Animal Nutrition, Human Nutrition, Aquaculture and Vitamin pre-mixes.

QC - Male
Qly : B. Pharmacy & MSc
Exp : 2 to 3 years
Skill : Handling of HPLC - Analysis

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Indoco Remedies Ltd., is a fully integrated, research-oriented pharma company engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients (APIs). We have seven decades of presence in the Indian Pharma market and a strong foothold in the international market across 55 countries. Indoco, a USD 166 million company, employs around 6000 personnel, including over 300 skilled scientists.

Bioplus is a family majority owned business with over 500 employees, multiple manufacturing sites and business in over 50 countries. Our products are focused on naturally sourced, renewable resource compounds validated by advanced science. Our focus is on licensed and OTC (nutritional) pharmaceuticals or healthcare products, novel drug delivery, excellence in carbohydrate chemistry and biopharmaceuticals.

The goal of the trial, known as HIV-CORE 0052, is to evaluate the safety, tolerability, and immunogenicity of the HIVconsvX vaccine – a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.

Thirteen healthy, HIV-negative adults, aged 18-65 and who are considered not to be at high risk of infection, will initially receive one dose of the vaccine followed by a further booster dose at four weeks.

AstraZenecas proposed acquisition of Alexion Pharmaceuticals, Inc.has achieved an important step towards completion by having cleared the European Commission review.

The clearance follows competition clearances in the United States, Japan and other countries globally, with a complete list available on astrazeneca.com. Regulatory clearance in the UK is pending and remains a requirement to complete the deal.

Merck known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.